{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:29:00Z","timestamp":1788013740107,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007729","name":"Ministerie van Buitenlandse Zaken","doi-asserted-by":"publisher","award":["project AF16012"],"award-info":[{"award-number":["project AF16012"]}],"id":[{"id":"10.13039\/501100007729","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nexira France","award":["Nexira France"],"award-info":[{"award-number":["Nexira France"]}]},{"name":"Wecare Probiotics Co., Ltd.","award":["Wecare Probiotics Co., Ltd. (Suzhou, Jiangsu, China)"],"award-info":[{"award-number":["Wecare Probiotics Co., Ltd. (Suzhou, Jiangsu, China)"]}]},{"DOI":"10.13039\/501100020550","name":"Naturex","doi-asserted-by":"publisher","award":["Naturex"],"award-info":[{"award-number":["Naturex"]}],"id":[{"id":"10.13039\/501100020550","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Winclove Probiotics B.V.","award":["Winclove Probiotics B.V."],"award-info":[{"award-number":["Winclove Probiotics B.V."]}]},{"name":"Bioiberica Spain","award":["Bioiberica Spain"],"award-info":[{"award-number":["Bioiberica Spain"]}]},{"name":"Roquette France","award":["Roquette France"],"award-info":[{"award-number":["Roquette France"]}]},{"name":"Ingredia, France","award":["Ingredia, France"],"award-info":[{"award-number":["Ingredia, France"]}]},{"name":"Ingredion USA","award":["Ingredion USA"],"award-info":[{"award-number":["Ingredion USA"]}]},{"name":"Darling Ingredients USA","award":["Darling Ingredients USA"],"award-info":[{"award-number":["Darling Ingredients USA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nutr"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To date, no adequate treatment for irritable bowel syndrome with predominant constipation complaints (IBS-C) is available. Fibers with prebiotic properties and probiotic compounds have shown promise in relieving IBS-C-related complaints. We aimed to determine the effects of a 4-week intervention with either an Acacia fiber (AF) with prebiotic properties or a probiotic <jats:italic>Bifidobacterium Lactis<\/jats:italic> (BLa80) supplement, compared to a control supplement, on stool pattern, IBS symptoms and Quality of Life (QoL), in IBS-C individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A parallel, double-blind, randomized controlled trial involving 180 subjects meeting the ROME IV criteria for IBS-C was conducted. Following a 4-week observation period, subjects received either AF (10\u00a0g), Probiotic BLa80 (4\u00a0g; 2\u2009\u00d7\u200910<jats:sup>11<\/jats:sup> CFU\/g) or a maltodextrin placebo (10\u00a0g) daily for 4 weeks. Subjects reported daily information on stool pattern and gastrointestinal complaints. Before and after each 4-week period, questionnaires on symptom severity, constipation symptoms, anxiety and depression and QoL were completed. Stool mass was measured for 5-days before and after the intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Stool frequency significantly improved in the AF and Probiotic BLa80 groups compared to placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>P<\/jats:italic>\u2009=\u20090.02, respectively). Probiotic BLa80 showed a significant reduction in IBS symptom severity (<jats:italic>P<\/jats:italic>\u2009=\u20090.03), for AF a trend towards decreased constipation symptoms (PAC-SYM, <jats:italic>P<\/jats:italic>\u2009=\u20090.10) was observed. No significant changes in stool consistency, stool mass or QoL measures were observed between the AF and Probiotic BLa80 compared to placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Daily dietary supplementation with Acacia fiber and probiotic supplements might help IBS-C patients by relieving IBS-related complaints compared to a placebo supplement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number of clinical trial<\/jats:title>\n            <jats:p>The trial is registered at ClinicalTrials.gov: NCT04798417: Study Details | Nutrition to Relieve IBS Constipation | ClinicalTrials.gov.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00394-024-03398-8","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T17:02:24Z","timestamp":1713891744000},"page":"1983-1994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial"],"prefix":"10.1007","volume":"63","author":[{"given":"Lonneke","family":"JanssenDuijghuijsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9679-6925","authenticated-orcid":false,"given":"Maartje","family":"van den Belt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Rijnaarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Guillemet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Witteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"7","key":"3398_CR1","doi-asserted-by":"publisher","first-page":"e13802","DOI":"10.1111\/nmo.13802","volume":"32","author":"M Camilleri","year":"2020","unstructured":"Camilleri M (2020) Sex as a biological variable in irritable bowel syndrome. Neurogastroenterol Motil 32(7):e13802","journal-title":"Neurogastroenterol Motil"},{"key":"3398_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/IJGM.S126581","volume":"10","author":"AK Chandar","year":"2017","unstructured":"Chandar AK (2017) Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med 10:385\u2013393","journal-title":"Int J Gen Med"},{"issue":"2","key":"3398_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2036.2007.03376.x","volume":"26","author":"A Wald","year":"2007","unstructured":"Wald A et al (2007) The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 26(2):227\u2013236","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3398_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/apt.12789","volume":"40","author":"A Gu\u00e9rin","year":"2014","unstructured":"Gu\u00e9rin A et al (2014) Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. Aliment Pharmacol Ther 40(1):83\u201392","journal-title":"Aliment Pharmacol Ther"},{"key":"3398_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.parkreldis.2016.05.016","volume":"28","author":"E Svensson","year":"2016","unstructured":"Svensson E et al (2016) Constipation and risk of Parkinson\u2019s disease: a Danish population-based cohort study. Parkinsonism Relat Disord 28:18\u201322","journal-title":"Parkinsonism Relat Disord"},{"key":"3398_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2018.12.021","volume":"281","author":"K Sumida","year":"2019","unstructured":"Sumida K et al (2019) Constipation and risk of death and cardiovascular events. Atherosclerosis 281:114\u2013120","journal-title":"Atherosclerosis"},{"key":"3398_CR7","doi-asserted-by":"crossref","unstructured":"Sharma A, Rao S (2017) Constipation: Pathophysiology and Current Therapeutic Approaches, in Gastrointestinal Pharmacology, B. Greenwood-Van Meerveld, Editor. Springer International Publishing: Cham. pp. 59\u201374","DOI":"10.1007\/164_2016_111"},{"issue":"11","key":"3398_CR8","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1007\/s10620-022-07543-3","volume":"67","author":"T Wang","year":"2022","unstructured":"Wang T et al (2022) Fecal microbiota signatures are not consistently related to Symptom Severity in Irritable Bowel Syndrome. Dig Dis Sci 67(11):5137\u20135148","journal-title":"Dig Dis Sci"},{"key":"3398_CR9","doi-asserted-by":"crossref","unstructured":"\u00d6hman L, T\u00f6rnblom H, Simr\u00e9n M (2015) Crosstalk at the mucosal border: importance of the gut microenvironment in IBS Nat Rev Gastroenterol Hepatol, 12(1): pp. 36\u201349","DOI":"10.1038\/nrgastro.2014.200"},{"issue":"8","key":"3398_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/BF02234645","volume":"44","author":"JH Xing","year":"2001","unstructured":"Xing JH, Soffer EE (2001) Adverse effects of laxatives. Dis Colon Rectum 44(8):1201\u20131209","journal-title":"Dis Colon Rectum"},{"issue":"Suppl 2","key":"3398_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jhn.12114","volume":"27","author":"P Hayes","year":"2014","unstructured":"Hayes P et al (2014) A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet 27(Suppl 2):36\u201347","journal-title":"J Hum Nutr Diet"},{"issue":"27","key":"3398_CR12","first-page":"8898","volume":"20","author":"KA Jadallah","year":"2014","unstructured":"Jadallah KA, Kullab SM, Sanders DS (2014) Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 20(27):8898\u20138909","journal-title":"World J Gastroenterol"},{"issue":"10","key":"3398_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/ajg.2014.202","volume":"109","author":"AC Ford","year":"2014","unstructured":"Ford AC et al (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109(10):1547\u20131561 quiz 1546, 1562","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3398_CR14","first-page":"207","volume":"15","author":"M Naseer","year":"2020","unstructured":"Naseer M et al (2020) Therapeutic effects of Prebiotics on Constipation: a schematic review. Curr Clin Pharmacol 15(3):207\u2013215","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"3398_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","volume":"157","author":"R Pittayanon","year":"2019","unstructured":"Pittayanon R et al (2019) Gut microbiota in patients with irritable bowel syndrome\u2014a systematic review. Gastroenterology 157(1):97\u2013108","journal-title":"Gastroenterology"},{"key":"3398_CR16","doi-asserted-by":"crossref","unstructured":"Wang T et al (2022) Fecal microbiota signatures are not consistently related to Symptom Severity in Irritable Bowel Syndrome. Digestive Diseases and Sciences, pp 1\u201312","DOI":"10.1007\/s10620-022-07543-3"},{"issue":"7","key":"3398_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S2468-1253(20)30056-X","volume":"5","author":"V Andresen","year":"2020","unstructured":"Andresen V, Gschossmann J, Layer P (2020) Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol 5(7):658\u2013666","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3398_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/08910600310014377","volume":"15","author":"C Cherbut","year":"2003","unstructured":"Cherbut C et al (2003) Acacia Gum is a bifidogenic Dietary Fibre with High Digestive Tolerance in healthy humans. Microb Ecol Health Disease 15(1):43\u201350","journal-title":"Microb Ecol Health Disease"},{"issue":"6","key":"3398_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1017\/S0007114508981447","volume":"100","author":"W Calame","year":"2008","unstructured":"Calame W et al (2008) Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. Br J Nutr 100(6):1269\u20131275","journal-title":"Br J Nutr"},{"issue":"4","key":"3398_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/1758-2229.12056","volume":"5","author":"K Terpend","year":"2013","unstructured":"Terpend K, Possemiers S, Daguet D, Marzorati M (2013) Arabinogalactan and fructo-oligosaccharides have a different fermentation profile in the Simulator of the human intestinal microbial ecosystem (SHIME\u00ae). Environ Microbiol Rep 5(4):595\u2013603","journal-title":"Environ Microbiol Rep"},{"issue":"3","key":"3398_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1572-0241.2007.01631.x","volume":"103","author":"AE Bharucha","year":"2008","unstructured":"Bharucha AE et al (2008) Insights into normal and disordered bowel habits from bowel diaries. Am J Gastroenterol 103(3):692","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3398_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jn\/133.1.232","volume":"133","author":"U Palaniappan","year":"2003","unstructured":"Palaniappan U et al (2003) Implications of day-to-day variability on measurements of usual food and nutrient intakes. J Nutr 133(1):232\u2013235","journal-title":"J Nutr"},{"issue":"2","key":"3398_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11(2):395\u2013402","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3398_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/003655299750025327","volume":"34","author":"L Frank","year":"1999","unstructured":"Frank L et al (1999) Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 34(9):870\u2013877","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"3398_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/00365520510012208","volume":"40","author":"P Marquis","year":"2005","unstructured":"Marquis P et al (2005) Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 40(5):540\u2013551","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"3398_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/S0033291796004382","volume":"27","author":"PH Spinhoven","year":"1997","unstructured":"Spinhoven PH et al (1997) A validation study of the hospital anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27(2):363\u2013370","journal-title":"Psychol Med"},{"key":"3398_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1475-2891-12-75","volume":"12","author":"MT Streppel","year":"2013","unstructured":"Streppel MT et al (2013) Relative validity of the food frequency questionnaire used to assess dietary intake in the Leiden Longevity Study. Nutr J 12:75","journal-title":"Nutr J"},{"issue":"9","key":"3398_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920\u2013924","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"3398_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/jcm6110099","volume":"6","author":"BE Lacy","year":"2017","unstructured":"Lacy BE, Patel NK (2017) Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 6(11):99","journal-title":"J Clin Med"},{"issue":"2","key":"3398_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cgh.2017.09.043","volume":"16","author":"BP Chumpitazi","year":"2018","unstructured":"Chumpitazi BP et al (2018) Fructans exacerbate symptoms in a subset of children with irritable bowel syndrome. Clin Gastroenterol Hepatol 16(2):219\u2013225e1","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3398_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1365-2036.1998.00336.x","volume":"12","author":"JW McRorie","year":"1998","unstructured":"McRorie JW et al (1998) Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 12(5):491\u2013497","journal-title":"Aliment Pharmacol Ther"},{"issue":"40","key":"3398_CR32","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.3748\/wjg.14.6237","volume":"14","author":"Y-X Yang","year":"2008","unstructured":"Yang Y-X et al (2008) Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 14(40):6237\u20136243","journal-title":"World J Gastroenterol"},{"key":"3398_CR33","unstructured":"FDA, Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment. (2012)"},{"issue":"10","key":"3398_CR34","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/ajg.2011.201","volume":"106","author":"DA Drossman","year":"2011","unstructured":"Drossman DA et al (2011) Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Official J Am Coll Gastroenterology| ACG 106(10):1749\u20131759","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"issue":"11\u201312","key":"3398_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/apt.14349","volume":"46","author":"Y Yiannakou","year":"2017","unstructured":"Yiannakou Y et al (2017) The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference. Aliment Pharmacol Ther 46(11\u201312):1103\u20131111","journal-title":"Aliment Pharmacol Ther"},{"key":"3398_CR36","doi-asserted-by":"crossref","unstructured":"Camilleri M (2006) Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol, 40(3)","DOI":"10.1097\/00004836-200603000-00020"},{"issue":"3","key":"3398_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1365-2036.2002.01188.x","volume":"16","author":"P Marteau","year":"2002","unstructured":"Marteau P et al (2002) Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16(3):587\u2013593","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3398_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10620-020-06109-5","volume":"65","author":"M Pimentel","year":"2020","unstructured":"Pimentel M, Lembo A (2020) Microbiome and its role in irritable bowel syndrome. Dig Dis Sci 65(3):829\u2013839","journal-title":"Dig Dis Sci"},{"key":"3398_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijsu.2020.04.063","volume":"79","author":"Y Wen","year":"2020","unstructured":"Wen Y et al (2020) The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials. Int J Surg 79:111\u2013119","journal-title":"Int J Surg"},{"key":"3398_CR40","doi-asserted-by":"crossref","unstructured":"Agrawal A et al (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation, vol 29. Alimentary pharmacology & therapeutics, pp 104\u2013114. 1","DOI":"10.1111\/j.1365-2036.2008.03853.x"},{"issue":"1","key":"3398_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.12787","volume":"40","author":"G Sisson","year":"2014","unstructured":"Sisson G et al (2014) Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome\u2013a 12 week double-blind study. Aliment Pharmacol Ther 40(1):51\u201362","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"3398_CR42","doi-asserted-by":"publisher","first-page":"A163","DOI":"10.1136\/gut.2011.239301.345","volume":"60","author":"GC Parkes","year":"2011","unstructured":"Parkes GC, Chatoor D, Emmanuel A (2011) The probiotic VSL#3 increases scbm and reduces symptom severity scores in patients with functional constipation. Gut 60(Suppl 1):A163","journal-title":"Gut"},{"issue":"48","key":"3398_CR43","doi-asserted-by":"publisher","first-page":"10631","DOI":"10.3748\/wjg.v22.i48.10631","volume":"22","author":"A Lyra","year":"2016","unstructured":"Lyra A et al (2016) Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol 22(48):10631\u201310642","journal-title":"World J Gastroenterol"},{"issue":"8","key":"3398_CR44","first-page":"e9871","volume":"12","author":"IS Vahora","year":"2020","unstructured":"Vahora IS et al (2020) How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome. Cureus 12(8):e9871","journal-title":"Cureus"},{"issue":"8","key":"3398_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2036.2011.04602.x","volume":"33","author":"NC Suares","year":"2011","unstructured":"Suares NC, Ford AC (2011) Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 33(8):895\u2013901","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3398_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.amjms.2016.09.014","volume":"353","author":"T Yu","year":"2017","unstructured":"Yu T et al (2017) Effects of Prebiotics and Synbiotics on Functional Constipation. Am J Med Sci 353(3):282\u2013292","journal-title":"Am J Med Sci"},{"issue":"6","key":"3398_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S2468-1253(21)00023-6","volume":"6","author":"M Bosman","year":"2021","unstructured":"Bosman M et al (2021) The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6(6):459\u2013473","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3398_CR48","first-page":"338","volume":"27","author":"LE Miller","year":"2014","unstructured":"Miller LE (2014) Study design considerations for irritable bowel syndrome clinical trials. Annals Gastroenterology: Q Publication Hellenic Soc Gastroenterol 27(4):338","journal-title":"Annals Gastroenterology: Q Publication Hellenic Soc Gastroenterol"},{"issue":"12","key":"3398_CR49","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1111\/nmo.12466","volume":"26","author":"JM Lackner","year":"2014","unstructured":"Lackner JM et al (2014) The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports. Neurogastroenterol Motil 26(12):1802\u20131811","journal-title":"Neurogastroenterol Motil"},{"issue":"5a","key":"3398_CR50","doi-asserted-by":"publisher","first-page":"91s","DOI":"10.1016\/S0002-9343(99)00086-8","volume":"107","author":"RC Spiller","year":"1999","unstructured":"Spiller RC (1999) Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 107(5a):91s\u201397s","journal-title":"Am J Med"}],"updated-by":[{"DOI":"10.1007\/s00394-025-03586-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000}}],"container-title":["European Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-024-03398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00394-024-03398-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-024-03398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:43:09Z","timestamp":1743129789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00394-024-03398-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3398"],"URL":"https:\/\/doi.org\/10.1007\/s00394-024-03398-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00394-025-03586-0","asserted-by":"object"}]},"ISSN":["1436-6207","1436-6215"],"issn-type":[{"value":"1436-6207","type":"print"},{"value":"1436-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figure 2 has been updated due to incorrect y-axis settings in R, the data was truncated in the figure 2 and several figure captions have mistakenly been embedded within the text paragraphs instead of being placed below the figures. This mistakes have been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00394-025-03586-0","URL":"https:\/\/doi.org\/10.1007\/s00394-025-03586-0","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DG is employed by Nexira, France, all other authors declare no conflict of interest. No brand names or specific products were communicated to the study subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}